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ABSTRACT:
Aim: Endothelin-receptor antagonists may be a novel therapeutic strategy
for diabetic nephropathy, but their use remains controversial. This meta-
analysis seeks to evaluate the effectiveness and safety of endothelin-
receptor antagonists for patients with diabetic nephropathy.
Methods: Literature reviews of the PubMed, EMBASE and CENTRAL data-
bases were conducted to identify randomized controlled trials (RCTs) com-
paring endothelin-receptor antagonist treatment with placebo in patients
with diabetic nephropathy. Quality assessment was performed by using the
Cochrane Handbook’s tools for assessing risk of bias; meta-analysis was
conducted by RevMan 5.3.
Resutls: Five RCTs (n = 2034 patients) were included for analysis. Compared
with placebo, endothelin-receptor antagonists showed significant benefits
for lowering albuminuria (five trials, n = 2034 patients; SMD 0.66 95% con-
fidence interval (CI) 0.56 to 0.76), but there was no significant difference in
the risk of death (two trials, n = 1674 patients; RR 1.49 95% CI 0.81 to 2.76).
In addition, risk of cardiovascular events and other serious adverse events
were significantly higher in the endothelin-receptor antagonists group than
the placebo group (four trials, n = 1956 patients; RR 1.45 95% CI 1.07 to 1.97;
five trials, n = 2034 patients; RR 1.32 95% CI 1.10 to 1.58).
Conclusion: Endothelin-receptor antagonists can reduce albuminuria in
patients with diabetic nephropathy, although use resulted in more serious
adverse events compared with placebo. There is a potential need for further
RCTs, which has larger sample size and longer duration.
Diabetic nephropathy is a leading cause of end stage renal
disease in many countries. Despite attempts at rigorous
control of hyperglycaemia and hypertension, some patients
with diabetic nephropathy still experience cardiovascular or
renal events.1 Many clinical studies have confirmed that
renin angiotensin system (RAS) inhibitors (angiotensin con-
verting enzyme (ACE) inhibitors or angiotensin II receptor
blockers (ARB)) can reduce albuminuria in patients with
diabetic nephropathy, and delay progression of chronic
kidney disease. These agents can cause hyperkalaemia
and creatinine elevation, making their use in patients
with decreased kidney function.2,3 Despite this potential
risk, endothelin-receptor (ER) antagonists have been used
as a novel treatment option for patients with diabetic
nephropathy.4
Endothelins are proteins that are produced by many cells
and contribute to hypertension. Endothelin-1 is an isoform
of endothelins that can activate both endothelin A receptor
(ETAR) and endothelin B receptor (ETBR). It has been con-
firmed that the levels of circulating and renal endothelin-1
are elevated in patients with diabetes and in preclinical
models. The activation of glomerular ETAR can promote the
proliferation of podocyte and mesangial cells, leading to
albuminuria and renal dysfunction.5–7 Previous clinical trials
have revealed that ER antagonists can reduce albuminuria
in patients with diabetic nephropathy, regardless of the
involvement of ETAR.8,9 This suggests that ER antagonists
may be a novel and beneficial drug for diabetic nephropa-
thy.10 However, Mann et al. (2010) reported an early termi-
nation of a trial of ER antagonists that was prompted by
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safety concerns with avosentan, including hypervolaemia,
congestive heart failure, hypotension and anaemia.9 There-
fore, potential morbidity risks must be considered. In view of
scarcity of systematic research in the area, we seek to fill a
gap in the literature through meta-analysis of the effective-
ness and safety of endothelin-receptor antagonists for
patients with diabetic nephropathy.
METHODS
Data sources and searches
We conducted a literature review of Pubmed (January 1966 to
December 2014), EMBASE (1980 to December 2014), CENTRAL
(searched December 2014). Specified search terms included
‘endothelin-receptor antagonists’, ‘atrasentan’, ‘avosentan’, ‘dia-
betic’ and ‘random’. These searches were followed by manual review
of the identified trial publications.
Trials selection
The initial sample included all randomized controlled trials (RCTs),
in which patients with diabetic nephropathy received endothelin-
receptor antagonists. The first period of randomized cross-over
studies were also considered for inclusion.
Eligible trials included: (i) patients 18 years of age or older; with
(ii) a diabetes diagnosis of a minimum of 4 weeks; (iii) a measured
estimated glomerular filtration rate (eGFR) > 20 mL/min per
1.73 m2 or serum creatinine <3 mg/dL; and (iv) microalbuminuria or
macroalbuminuria (urinary albumin-to-creatinine ratio (UACR)
>3 mg/mmol or UAER > 0.2 mg/min).
Individuals were excluded if they had received a diagnosis of
an immune-related renal diseases, such as minimal change disease,
IgA nephropathy, membranous nephropathy, focal segmental
glomerular sclerosis, and lupus nephritis. Patients of all racial, eth-
nicity, and nationality groups were included.
Eligible trials included intervention comparisons of atrasentan
versus placebo, avosentan versus placebo, and bosentan versus
placebo. Clinical outcomes included primary (all-cause mortality,
cardiovascular events), and secondary measures (albuminuria
(changes of urine albumin-to-creatinine ratio (UACR) or urinary
albumin excretion rate (UAER)) and estimated glomerular filtration
rate (eGFR). Safety outcomes assessed included adverse events, sys-
tolic (SBP) and diastolic (DBP) blood pressure, peripheral oedema,
and anaemia.
Data extraction and risk of bias assessment
Two authors independently abstracted data using a standard data
extraction form. If an individual study was represented in more than
one publication, the data were combined.11 Discrepancies in data
extraction were discussed by the group and resolved by Ping Fu, the
project director.
Data extraction variables included patient characteristics, inter-
ventions, outcome measures, and treatment periods. The assessment
of risk of bias included the examination of sequence generation,
allocation concealment, blinding, incomplete outcomes, selective
reporting, and other biases.
Measure of treatment effect
For binary outcomes (e.g. mortality, cardiovascular events, adverse
events), the results of intervention were expressed as risk ratio (RR)
with 95% confidence intervals (CI). For continuous outcomes (e.g.
changes of UACR, eGFR, SBP, and DBP), the results were expressed
as mean difference (MD) with 95% CIs. When different scales had
been applied, the SMD was used. Presence and extent of heteroge-
neity among studies was analyzed by using a χ2 test and I2 statistic.
Homogeneity is indicated by P-value >0.1 or I2 < 50%, making a
fixed-effect model appropriate. Measured probability less than 0.1 or
I2 > 50% may represent substantial heterogeneity. Where indicated
by the type of trial interventions, subgroup analyses were conducted
to explore any identified heterogeneity. A random-effect model was
used to incorporate unobservable heterogeneity across studies, a
common approach in meta-analysis. Of the five included trials, four
assessed at least two different doses of ER antagonists groups. For
each trial we collapsed all treatment doses of ER antagonists groups
into a single group for comparison with placebo. Combined data
were analyzed by Revman 5.3.12
RESULTS
Result of searches
Of the 647 potentially eligible trials identified by electronic
searching, five RCTs (n = 2034 patients) met inclusion
criteria; screening processes and results are presented in
Fig. 1.8–10,13,14 The characteristic of five included trials were
shown in Table 1.
Risk of bias in included trials
All five included trials exhibited low risk of bias with respect to
sequence generation, allocation concealment, blinding, incom-
plete outcome and selective reporting. Two of these trials con-
tained other potential bias.14 TheMann 2010 trial discontinued
after a median follow-up of 4 months because patients experi-
enced adverse events of hypervolaemia and congestive heart
failure.9 The Wenzel 2009 trial included three authors who
Fig. 1 Flow diagram of search and selection.
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received benefits from a related pharmaceutical company, indi-
cating a potential conflict of interest. The author R.R.W. had
received consultant fees from SPEEDEL Pharma AG. The other
two authors T.L. and S.K. had been used by and hold stock in
SPEEDEL Pharma AG.14 Of the five included trials, four trials
were registered with the ClinicalTrials.gov database.8–10,13
Details of the risk of bias are shown in Table 2.
Results of meta-analysis
Primary outcomes
All-cause mortality. Two trials reported the all-cause mortal-
ity of patients with diabetic nephropathy.9,14 Of the 1674
patients, a total of 55 patient deaths occurred (3.6% (n = 42/
1162) in the treatment group, 2.5% (n = 13/512) in the
placebo group). In the Mann 2010 and the Wenzel 2009, the
rates of deaths were 3.6% and 1.7%, respectively.9,14 There
was no statistically significant difference in the risk of death
among patients treated with ER antagonists as compared to
placebo (two trials, n = 1674 patients; RR 1.49 95% CI 0.81
to 2.76, see Fig. 2a). There was no statistical evidence of
heterogeneity (I2 = 0%, P = 0.20). In the subgroup analysis,
there was also no significant difference in patient death for
individual types and doses of ER antagonists groups as com-
pared with the placebo group.
Cardiovascular events. Four trials reported the rate of cardio-
vascular events. There were defined as coronary artery
disease, nonfatal acute myocardial infarction, stroke or con-
gestive heart failure.8–10,14 A total of 194 cardiovascular
events occurred in 1956 patients (9.9%; 10.7% (n = 146/
1367) in the treatment group, 8.1% (n = 48/589) in the
placebo group). The meta-analysis indicated that risk of car-
diovascular events was statistically significant higher in treat-
ment group than placebo group (four trials, n = 1956
patients; RR 1.45 95% CI 1.07 to 1.97, see Fig. 2b). There
was no statistical evidence of heterogeneity (I2 = 0%,
P = 0.88). This result was dominated by the Mann 2010 trial
that contributed 95.5% weight to the summary estimate.
Mann 2010 trial reported a higher risk of cardiovascular
events in treatment group than the placebo group but the
other three trials reported no significant difference.8–10,14
Secondary outcomes
Albuminuria. To assess the albuminuria in patients with
diabetic nephropathy, all five trials reported the changes of
UACR or UAER from baseline to each final observation. Four
trials used UACR8–10,13 and one trial used UAER.14 We chose
SMD as a summary statistic in the meta-analysis because
different scales had been applied. There was a statistically
Table 1 Characteristics of included trials
Study ID Study
type
No.
patients
Type of patients Interventions Outcomes Treatment period
Kohan et al. 20118 RCT 89 Diabetic nephropathy
eGFR > 20 mL/min per 1.73 m2
UACR of 100–3000 mg/g
Mean age of 64 years
Duration of diabetes >1 year
Atrasentan 0.25 mg/day (n = 22)
Atrasentan 0.75 mg/day (n = 22)
Atrasentan 1.75 mg/day (n = 22)
Placebo (n = 23)
1. UACR
2. CV events†
3. Adverse events
8 weeks
Mann et al. 20109 RCT 1392 Diabetic nephropathy
Scr of 1.3 to 3.0 mg/dL
UACR ≥ 309 mg/g
Mean age of 61 years
Duration of diabetes >3 years
Avosentan 25 mg/day (n = 455)
Avosentan 50 mg/day (n = 478)
Placebo (n = 459)
1. Death
2. CV events†
3. eGFR
4. UACR
5. Adverse events
4 to 16 months
Rafnsson et al. 201213 RCT 56 Diabetes and microalbuminuria
Scr < 3.0 mg/dL
UACR > 3 mg/mmol
mean age of 62 years
Duration of diabetes >2 years
Bosentan 250 mg/day (n = 28)‡
Placebo (n = 28)
1. UACR
2. Scr
3. Adverse events
4 weeks
Wenzel et al. 200914 RCT 286 Diabetic nephropathy
Scr <3.0 mg/dL
UAER of 0.2 to 5.6 mg/min
Mean age of 59 years
Duration of diabetes >4 weeks
Avosentan 5 mg/day (n = 59)
Avosentan 10 mg/day (n = 57)
Avosentan 25 mg/day (n = 60)
Avosentan 50 mg/day (n = 53)
Placebo (n = 57)
1. Death
2. CV events†
3. UAER
4. eGFR
5. Adverse events
12 weeks
Zeeuw et al. 201410 RCT 211 Diabetic nephropathy
eGFR of 30–75 mL/min per 1.73 m2
UACR > 300–3500 mg/g
Mean age of 65 years
Duration of diabetes >1 year
Atrasentan 0.75 mg/day (n = 78)
Atrasentan 1.25 mg/day (n = 83)
Placebo (n = 50)
1. UACR
2. CV events†
3. eGFR
4. Adverse events
12 weeks
†CV, cardiovascular. ‡Bosentan at 62.5 mg twice daily for 2 weeks and increased to 125 mg twice daily for 2 weeks.
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significant difference in lowering albuminuria among
patients treated with ER antagonists compared with placebo
(5 trials, n = 2034 patients; SMD 0.66 95% CI 0.56 to 0.76,
see Fig. 3a). There was no statistical evidence of heterogene-
ity (I2 = 24%, P = 0.26). In the subgroup analysis, as com-
pared to placebo groups there were significant reductions of
albuminuria in patients receiving total daily doses of
atrasentan 0.75 mg, atrasentan 1.25 mg, atrasentan 1.75 mg,
avosentan 5 mg, avosentan 10 mg, avosentan 25 mg
and avosentan 50 mg, respectively, but no significant differ-
ences for those prescribed atrasentan 0.25 mg and bosentan
250 mg.
Furthermore, two trials reported the number of patients
who achieved 40% or greater reductions in UACR.8,10 The
results of meta-analysis also showed no statistically signifi-
cant difference in lowering albuminuria in the treatment
group compared with the placebo group (two trials, n = 300
patients, RR 4.16 95% CI 2.01 to 8.61).
eGFR. Three trials reported the changes of eGFR from base-
line to each final observation.8,10 The meta-analysis showed
that eGFR significantly increased among patients treated
with ER antagonists compared with placebo (three trials,
n = 1889 patients, MD 1.23 95% CI 0.51 to 1.95, see Fig. 3b).
In the subgroup analysis, there were statistically significant
increases in eGFR in patients receiving total daily doses of
avosentan 25 mg and avosentan 50 mg, but no differences
for patients prescribed atrasentan 0.75 mg, atrasentan
Fig. 2 (a) Endothelin-receptor antagonists versus placebo on mortality. (b) Endothelin-receptor antagonists versus placebo on cardiovascular events.
Fig. 3 (a) Endothelin-receptor antagonists versus placebo on changes of albuminuria. (b) Endothelin-receptor antagonists versus placebo on changes of estimated
glomerular filtration rate (eGFR).
ER antagonists for DN: a meta-analysis
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1.25 mg, avosentan 5 mg and avosentan 10 mg when com-
pared with the placebo group.
Safety outcomes
Adverse events. All five trials reported adverse events with
ER antagonists, including oedema, hypervolaemia, hypoten-
sion, anaemia, and dyspnea.8–10,13,14 Almost 67% of all
patients (n = 1357) reported at least one adverse event,
68.1% of the treatment group (n = 965) and 63.5% of the
placebo group (n = 392). The majority of these adverse
events were mild or moderate in severity and were consid-
ered unrelated to treatment. Treatment groups experienced a
higher rate of adverse events as compared to placebo, but not
significantly so (five trials, n = 2034 patients; RR 1.06 95% CI
0.99 to 1.14, see Fig. 4a).
There was no statistical evidence of heterogeneity
(I2 = 0%, P = 0.56). The serious adverse events occurred
more often with the use of ER antagonists and a total of
22.5%, or n = 458/2034 patients had at least one serious
adverse event in 2034 patients (23.9% (n = 338/1417) in the
treatment group, 19.4% (n = 120/617) in the placebo
group). The meta-analysis showed that the risk of serious
adverse events was statistically significantly higher in treat-
ment groups than placebo groups (five trials, n = 2034
patients; RR 1.32 95% CI 1.10 to 1.58, see Fig. 4b). There
was also no statistical evidence of heterogeneity (I2 = 0%,
P = 0.81).
Blood pressure. All five trials reported the changes of
SBP and DBP.8–10,13,14 There were statistically significant
reductions of SBP and DBP in the treatment group as com-
pared with the placebo (five trials, n = 2034 patients; SBP,
MD 3.88 95% CI 2.40 to 5.36; DBP, MD 2.65 95% CI 1.01 to
4.30 ).
Peripheral oedema. All the five trials reported the peripheral
oedema events.8–10,13,14 There were no statistically significant
differences in treatment groups as compared with placebo
(five trials, n = 2034 patients; RR 1.11 95% CI 0.90 to
1.36).
Anaemia. Four trials reported the changes in haemoglobin
from baseline to each final observation.8,10,13,14 There was
a statistically significant reduction of haemoglobin for
patients in treatment groups compared with placebo groups
(four trials, n = 642 patients. MD 0.69, 95% CI 0.51 to
0.87).
Two trials reported the rate of anaemia and a total of 143
anaemia events occurred in 1678 patients (8.5%; 10.8%
(n = 125/1162) in the treatment group, 3.5% (n = 18/516) in
the placebo group).9,14 There was a significant increase of risk
of anaemia for treatment group patients compared with
placebo groups (two trials, n = 1678 patients. RR 3.22 95%
CI 1.99 to 5.20).
DISCUSSION
Summary of main result
Endothelin-receptor antagonists have been proven to
effectively lower albuminuria in diabetic rat models.15 This
Fig. 4 (a) Endothelin-receptor antagonists versus placebo on adverse events. (b) Endothelin-receptor antagonists versus placebo on serious adverse events.
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meta-analysis further revealed that ER antagonists were ben-
eficial in lowering albuminuria among patients with diabetic
nephropathy. However, compared with placebo, ER antago-
nists resulted in more serious adverse events and higher risks
of cardiovascular events, hypotension and anaemia.
Applicability of evidence
Patient age and types of endothelin-receptor antagonists are
factors associated with higher risks of cardiovascular and
adverse events as evidenced in this meta-analysis. Most
patients with diabetic nephropathy were older than 60 years
and were likely to endure hypotension and oedema. Some
studies had proven that hypotension and oedema may lead
to cardiovascular endpoints.16,17 The differential inhibition
effect of endothelins may also contribute to heart failures, as
the inhibition effect of ETBR may lead to fluid and salt reten-
tion, partially mediated via the epithelial sodium transporter
in tubular cells,18 resulting in congestive heart failure. There
was no head-to-head clinical trial of selective ETA vs. ETA/B
antagonists in patients with diabetic nephropathy. Further
RCTs will need to compare the effectiveness of ETAR with
ETA/BR antagonists.
Quality of evidence
Four trials in the meta-analysis had relatively small sample
sizes;8,10,13,14 hence there is a likelihood that the results of
meta-analysis were largely driven by a single trial with the
largest sample size, which is the Mann 2011 trial. However,
this trial was terminated prematurely after a median
follow-up of 4 months because of the significant safety con-
cerns related to cardiovascular events.9
Limitation of this meta-analysis
Four trials assessed more than two doses of endothelin-
receptor antagonists, when compared with a common
placebo group.8–10,14 This precludes a direct meta-analysis of
pairwise comparisons; a unit-of-analysis error would arise if
the placebo group was included more than twice in the
same meta-analysis. We conducted the meta-analysis
from the recommend method in the Cochrane handbook,
after combining all ER antagonists groups into a single
treatment.11
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